Efficacy and Safety Study of Nitazoxanide (NTX) in the Treatment of Patients With SARS-CoV-2 Virus Infection (COVID-19)
Status:
Recruiting
Trial end date:
2020-12-26
Target enrollment:
Participant gender:
Summary
Evaluation of the efficacy and safety of NTX in adult patients (≥18 years and <60 years),
with SARS-CoV-2 infection with mild symptoms of COVID-19, compared to a placebo control arm.
135 patients will be randomized to either Nitazoxanide (n=90) or placebo (n=45) (2:1). Simple
blind design. Primary endpoint: eradication of virus from patients' respiratory tract
secretions by the 7th day of treatment.